Dupuytren’s contracture is a benign fibromatosis of the palmar and digital fascia of the hand of uncertain etiology, resulting in nodules and cords beneath the skin of the palm of the hands that may lead to the development of contractures. Surgical intervention is often considered when metacarpophalangeal (MP) joint contracture is 30° or more, or when there is any degree of proximal interphalangeal (PIP) joint contracture. Collagenase clostridium histolyticum (CCH) is a nonsurgical, minimally invasive enzymatic drug indicated for the treatment of adult patients with Dupuytren’s contracture (DC) and palpable cord. CCH has been available for approximately 3.5 years, and postapproval experience indicates that the effectiveness of CCH is equivalent to or better than efficacy observed in clinical trials, as seen by lower injection rates to achieve clinical success. Postapproval experience has shown a risk-benefit profile that favors CCH for patients not indicated for surgery based on current recommendations and shows also that treating earlier-stage vs later-stage joint contracture results in significantly better outcomes on average. Postapproval surveillance reveals a safety profile similar to that observed in clinical trials. Nonserious adverse events are mainly local reactions; tendon rupture, a serious adverse event, is reported rarely in the clinical practice setting and at a lower rate than in clinical trials. Risk Evaluation and Mitigation Strategy (REMS) training is designed to mitigate benefit vs risk to achieve safe and effective use of CCH.
American Society for Surgery of the Hand. Level of evidence guidelines. Available at: http://www.assh.org. Accessed 6 Jul 2012.
Auxilium Pharmaceuticals Inc. Briefing document for collagenase clostridium histolyticum (AA4500) in the treatment of advanced Dupuytren’s disease. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM182015.pdf.
Auxilium Pharmaceuticals Inc. BLA 125338 Xiaflex® (collagenase clostridium histolyticum) risk evaluation and mitigation strategy (REMS). Malvern, PA: Auxilium Pharmaceuticals, Inc.; February, 2012.
Auxilium Pharmaceuticals Inc. Xiaflex® (collagenase clostridium histolyticum) [prescribing information]. Malvern, PA: Auxilium Pharmaceuticals, Inc.; December, 2013.
Becker GW, Davis TRC. The outcome of surgical treatments for primary Dupuytren’s disease—a systematic review. J Hand Surg (Br). 2010;35:623–6. CrossRef
Blazar P, Belsky MR, Tursi J, Smith T. Safety and efficacy of collagenase clostridium histolyticum injection to treat Dupuytren’s fixed flexion >5° to <20°. Presented at: 67th Annual Meeting of the American Society for Surgery of the Hand, September 6–8, 2012, Chicago, IL.
Burge P. Genetics of Dupuytren’s disease. Hand Clin. 1999;15:63–71. PubMed
Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg [Am]. 2014;39:57–64. CrossRef
Couceiro J, Savvidou C, Kaufman CL, Moreno R, Tien HY. Effect of joint contracture on patient satisfaction in collagenase injection treatment of Dupuytren’s disease. Presented at: 67th Annual Meeting of the American Society for Surgery of the Hand, September 6–8, 2012, Chicago, IL.
Curtin C, Cohen B. Dupuytren’s contracture recurrence after treatment with collagenase clostridium histolyticum diathesis and other disease factors. Presented at: American Association for Hand Surgery, January 9–12, 2013, Naples, FL.
DeMarco PJ, Beall AD, Matsumoto AK, Baraf HSB, Mandel DR. Retrospective review of the use of ultrasound guidance while injecting collagenase clostridium histolyticum (Xiaflex®) into a Dupuytren’s cord. Presented at: Annual Meeting of the American Association for Hand Surgery, January 9–12, 2013, Naples, FL.
Denkler K. Surgical complications associated with fasciectomy for Dupuytren’s disease: a 20-year review of the English literature. Eplasty. 2010;10:116–33.
European Medicines Agency. Assessment report: Xiapex. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002048/WC500103376.pdf. Accessed 12 Jul 2013.
Gill K, Friedman D, Litts CS. Spontaneous cord rupture after collagenase clostridium histolyticum injection for treatment of Dupuytren’s disease. Presented at: 30th Annual Adrian E. Flatt Residents and Fellows Conference in Hand Surgery, September 5, 2012, Chicago, IL.
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg [Am]. 2010;35:2027–38. CrossRef
Hurst L. Dupuytren’s contracture. In: Wolfe SW, Hotchkiss RN, Pederson WC, et al., editors. Green’s operative hand surgery. 6th ed. Philadelphia: Churchill Livingstone; 2011. p. 141–58. CrossRef
Hurst LC, Badalamente M, Smith T, Holzer LA, Holzer G, Zhang P, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture [letters to editor and authors’ reply]. N Engl J Med. 2009;361:2578–80. CrossRef
Hurst LC, Badalamente MA, et al. Histopathology and cell biology. In: Tubiana R, Leclercq C, Hurst LC, editors. Dupuytren’s disease. London: Martin Dunitz Ltd; 2000. p. 59–77.
Hurst LC, Badalamente MA, Wang ED. Injectable clostridial collagenase: striving toward nonoperative treatment options for fibroproliferative disorders. Available at: http://www.aaos.org/research/committee/research/kappa/kd2009_hurst.pdf. Accessed 19 Mar 2013.
Ines M, Silverio NM, Erdogan-Ciftci E. Cost-minimization analysis of collagenase clostridium histolyticum compared with fasciectomy in patients with Dupuytren’s contracture in Portugal [abstract]. Value Health. 2011;14:A310. CrossRef
Kaplan FTD, Hentz VR, Tursi J, Kaufman G, Smith T. Patterns of recurrent contracture in patients with Dupuytren’s disease 3 years following successful treatment with collagenase clostridium histolyticum. Presented at: 67th Annual Meeting of the American Society for Surgery of the Hand, September 6–8, 2012, Chicago, IL.
Leclercq C. Clinical presentation. In: Tubiana R, Leclercq C, Badalamente MA, editors. Dupuytren’s disease. London: Martin Dunitz Ltd; 2000. p. 79–96.
Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P. Direct and indirect costs associated with Dupuytren’s contracture. J Med Econ. 2012;15:1–8. CrossRef
Malone DC, Armstrong EP. Cost-effectiveness of collagenase clostridium histolyticum, limited fasciectomy, and percutaneous needle fasciotomy in the treatment of Dupuytren’s contracture [abstract]. Value Health. 2012;15:A38–9. CrossRef
Mikkelsen OA. The prevalence of Dupuytren’s disease in Norway: a study in a representative population sample of the municipality of Haugesund. Acta Chir Scand. 1972;138:695–700. PubMed
Moon E, Crivello K, Potter H, Wolfe S. Does collagenase injection disrupt or digest the Dupuytren’s cord? A magnetic resonance imaging study [abstract]. J Hand Surg [Am]. 2012;37 suppl 8:15–6. CrossRef
Peimer CA, Blazar P, Coleman S, Kaplan FT, Smith T, Tursi JP, et al. Dupuytren’s contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS): 3-year data. J Hand Surg [Am]. 2013;38:12–22. CrossRef
Peimer CA, Osterman AL. Patient and physician satisfaction with injectable clostridial collagenase for Dupuytren’s disease. Presented at: 77th Annual Meeting of the American Academy of Orthopaedic Surgeons, March 9–13, 2010, New Orleans, LA.
Peimer CA, Skodny P, Mackowiak JI. Collagenase clostridium histolyticum for Dupuytren contracture: patterns of use and effectiveness in clinical practice. J Hand Surg [Am]. 2013;38:2370–6. CrossRef
Raven RB 3rd, Kushner H, Nguyen D, Naam N, Curtin C. Analysis of efficacy and safety of treatment with collagenase clostridium histolyticum among subgroups of patients with Dupuytren contracture. Ann Plast Surg. 2013;Mar 18.
Rayan GM. Dupuytren’s disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89:189–98. PubMed
Sau C, Bounthavong M, Tran JN, Wilson RL. Cost-utility analysis of collagenase clostridium histolyticum, limited fasciectomy, and percutaneous needle fasciotomy in Dupuytren’s contracture [abstract]. Value Health. 2011;14:A128. CrossRef
Skirven TM, Bachoura A, Jacoby SM, Culp RW, Osterman AL. The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by Dupuytren disease and treated with collagenase injection. J Hand Surg [Am]. 2013;38:684–9. CrossRef
Taylor AJ, Mandel D, Britton EN, Frazier JL, Kaufman G, Tursi J. Design and construction of a decision tree for treatment of Dupuytren’s contracture. Presented at: 67th Annual Meeting of the American Society for Surgery of the Hand, September 6–8, 2012, Chicago, IL.
Trojian TH, Chu SM. Dupuytren’s disease: diagnosis and treatment. Am Fam Physician. 2007;76:86–9. PubMed
Tursi J, Coleman S, Mackowiak J. Use of collagenase clostridium histolyticum in earlier stage vs. later stage Dupuytren’s contracture results in better outcomes. Presented at: 1st Annual Combined Meeting of the American Society for Surgery of the Hand and the Australian Hand Surgery Society, March 22–25, 2012, Kauai, HI.
van Rijssen AL, Gerbrandy FS, ter Linden H, Klip H, Werker PM. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren’s disease: a 6-week follow-up study. J Hand Surg [Am]. 2006;31:717–25. CrossRef
Werker PM, Pess GM, van Rijssen AL, Denkler K. Correction of contracture and recurrence rates of Dupuytren contracture following invasive treatment: the importance of clear definitions. J Hand Surg [Am]. 2012;37:2095–105. CrossRef
Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase clostridium histolyticum, a nonsurgical treatment for adults with Dupuytren’s contracture: short-term results from two open-label studies, in the US (JOINT I) and Australia and Europe (JOINT II). J Hand Surg [Am]. 2013;38:2–11. CrossRef
- Postapproval clinical experience in the treatment of Dupuytren’s contracture with collagenase clostridium histolyticum (CCH): the first 1,000 days
Scott M. Schulze
James P. Tursi
- Springer US
Neu im Fachgebiet Chirurgie
Mail Icon II